ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0408

A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography

COSIMO BRUNI1, Alexandru Garaiman2, Lorenzo Tofani3, Suzana Jordan4, Carmen-Marina Mihai4, Rucsandra Dobrota4, Muriel ELHAI5, Mike Oliver Becker4, Marco Matucci-Cerinic3 and Oliver Distler6, 1University of Florence, Department of Rheumatology, Florence, Italy & Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Florence, Italy, 2University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3University of Florence, Florence, Italy, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 5Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 6Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland

Meeting: ACR Convergence 2021

Keywords: Computed tomography (CT), interstitial lung disease, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: High resolution computed tomography (conventional CT) represents the diagnostic gold standard for systemic sclerosis-related interstitial lung disease (SSc-ILD). A low-dose 9-slices (reduced) CT protocol was previously shown to be a highly sensitive tool to screen for ILD and to classify it into limited or extensive according to the Goh et al visual staging system (1). Histogram-based densitometry analysis is an automated quantitative evaluation of SSc-ILD, with mean lung attenuation, skewness, and kurtosis as main variables, recently merged into a Computerized Integrated Index (CII) (2). CII has shown good discrimination of SSc-ILD presence and association with the Goh et al staging on conventional CT. We aimed at testing the CII in reduced CT, in comparison to conventional CT, in discriminating for the presence and severity of SSc-ILD.

Methods: We analyzed prospectively collected conventional and reduced CT images of SSc patients followed at our tertiary referral center. The Goh et al staging (limited vs extensive ILD) was applied by an experienced radiologist. Conventional and reduced CT images were analyzed using the free-source software Horos to obtain the CII, named conventional and reduced CII respectively. We measured the association between CIIs and categories using generalized estimating equations (GEE). The predictive ability of CIIs was assessed in a ROC analysis.

Results: We enrolled 468 SSc patients, further described in the table 1: 427 had undergone at least one conventional CT (total 719 CTs), 345 at least one reduced CT (total 814 reduced CTs). Both CT and reduced CT images were available at the same visits for 243 patients (total 294 conventional + reduced CTs). The three groups were comparable in terms of ILD prevalence and extensive ILD (48% vs 45% vs 48% and 25% vs 21% vs 20%, in conventional CT, reduced CT and conventional + reduced CTs groups, respectively).

Both conventional and reduced CII significantly differentiated ILD vs non-ILD (mean conventional CII-0.46±0.15vs 0.67±0.09, p< 0.001 and mean reduced CII -0.50±0.17 vs 0.48±0.11, p< 0.001, respectively). Similarly, they separated limited vs extensive ILD (mean conventional CII -0.12±0.14 vs -1.48±0.21, p< 0.001, and mean reduced CII -0.25±0.13 vs -1.71±0.20, p< 0.001, respectively).

The two CIIs similarly predicted the presence of ILD [conventional CII AUC 0.72 (95% CI 0.66-0.77) vs reduced CII AUC 0.68 (95% CI 0.62-0.74); p=0.28, Figure 1A-B]. A similar performance was shown for extensive vs limited ILD [conventional CII AUC 0.77 (95% CI 0.68-0.87) vs reduced CII AUC 0.78 (95% CI 0.70-0.87), p=0.86, Figure 1C-D].

A cut-off for conventional CII< -0.96 (85% sensitivity, 62% specificity) or a reduced CII< -1.85 (85% sensitivity, 54% specificity) was chosen for an optimal sensitivity to detect extensive ILD.

Conclusion: We validated the ability of the CII to detect the presence of ILD and identified cut-offs for both conventional and reduced CII to discriminate between extensive versus limited ILD. Further validation of the proposed cut-offs is ongoing to further support its use in clinical practice and research.

References: 1) Goh et al, Am J Respir Crit Care Med 2008; 2)Bocchino et al, Sci Rep 2019

Table 1 – Characteristics of the study population

ROC curve analysis for conventional and reduced CII for discrimination of ILD presence and extensive ILD


Disclosures: C. BRUNI, Boehringer-Ingelheim, 1, 2; A. Garaiman, None; L. Tofani, None; S. Jordan, None; C. Mihai, Roche, 6, Boehringer-Ingelheim, 2, 6, Mepha Pharma, 6, MEDtalks Switzerland, 6; R. Dobrota, None; M. ELHAI, Gilead, 12, Travel Support for ACR 2019, BMS, 6, Roche, 12, Travel Support for Congress; M. Becker, None; M. Matucci-Cerinic, Merck, 5, 6, Actelion, 5, 6, Janssen, 6, Eli Lilly and Company, 6, Biogen, 6; O. Distler, AbbVie, 12, Project scoring fee for Rheumatology Grant, Amgen, 2, Eli Lilly, 2, Pfizer Inc, 2.

To cite this abstract in AMA style:

BRUNI C, Garaiman A, Tofani L, Jordan S, Mihai C, Dobrota R, ELHAI M, Becker M, Matucci-Cerinic M, Distler O. A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/a-histogram-based-densitometry-index-to-support-the-identification-and-the-assessment-of-severity-of-interstitial-lung-disease-in-systemic-sclerosis-applicability-in-conventional-and-low-dose-compute/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-histogram-based-densitometry-index-to-support-the-identification-and-the-assessment-of-severity-of-interstitial-lung-disease-in-systemic-sclerosis-applicability-in-conventional-and-low-dose-compute/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology